📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Discuva

1.1 - Company Overview

Discuva Logo

Discuva

Headquarter: United Kingdom
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of next-generation antibiotic discovery, Cambridge (UK)-based, established to address major gaps in the treatment of infective disease using proprietary methods, and developer of Ivonescimab (SMT112), a bispecific PD-1/VEGF antibody for oncology in Phase III trials for non-small cell lung cancer and other solid tumors, with over 1,600 patients treated.

Products and services

  • Ivonescimab (SMT112): A bispecific antibody targeting PD-1 and VEGF, engineered to potentially treat non-small cell lung cancer and other solid tumors across oncology indications
  • Next Generation antibiotic discovery: Proprietary methods-driven antibacterial discovery research, architected to address major gaps in current treatment of infective disease with antibiotics, leveraging Cambridge-based scientific pedigree
  • Phase III Clinical Trials: Advanced-stage evaluations of Ivonescimab in non-small cell lung cancer and other solid tumors, with over 1,600 patients treated across studies

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Discuva

Proof Diagnostics Logo

Proof Diagnostics

HQ: United States Website
  • Description: Provider of life sciences tools, diagnostics, and computational discovery solutions, offering a smart, portable CRISPR-based and other technology diagnostic system for rapid, low-cost, sensitive detection of infectious diseases (e.g., SARS-CoV-2, Flu A/B, RSV) and other diseases, OMEGA libraries of RNA-programmable non-Cas enzymes for genome engineering, and gene therapy services leveraging these tools.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Proof Diagnostics company profile →
IncellDx Logo

IncellDx

HQ: United States Website
  • Description: Provider of molecular diagnostics focused on detecting and monitoring life-threatening viral diseases, offering HPV OncoTect 3Dx assay quantifying E6/E7 mRNA for cervical cancer; incellKINE Long COVID in vitro diagnostic (CE marked); HPV E6/E7 mRNA probe; CMV mRNA probe (RUO); hybridization core reagents; and HPV control cells (RUO).
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full IncellDx company profile →
Adrenomed Logo

Adrenomed

HQ: Germany Website
  • Description: Provider of clinical-stage biopharmaceutical development focused on rescuing vascular integrity to save critically ill patients with limited treatment options, including the lead product candidate Adrecizumab, a first-in-class monoclonal antibody.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Adrenomed company profile →
Abac Therapeutics Logo

Abac Therapeutics

HQ: Spain Website
  • Description: Provider of precision antimicrobial drug discovery and development, creating first-in-class, pathogen-specific antibiotics for MDR Gram-negative infections. Offers the PasNas scalable, multiplexed platform to identify high-quality leads across compounds and bacterial species, and advances agents with suitable pharmacokinetics/toxicology, leveraging public-private collaborations to combat antimicrobial resistance.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Abac Therapeutics company profile →
DDL Logo

DDL

HQ: The Netherlands Website
  • Description: Provider of diagnostic solutions in molecular virology, bioinformatics, molecular bacteriology, and pathology, supporting clinical trials globally across five continents. Offers infectious disease and vaccine development expertise, oncology trial support, rare disease cell and gene therapy operations, biologics and biosimilars services from preclinical to post-market, and customized kit building for sample integrity.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full DDL company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Discuva

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Discuva

2.2 - Growth funds investing in similar companies to Discuva

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Discuva

4.2 - Public trading comparable groups for Discuva

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Discuva

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Discuva

What does Discuva do?

Discuva is a provider of next-generation antibiotic discovery, Cambridge (UK)-based, established to address major gaps in the treatment of infective disease using proprietary methods, and developer of Ivonescimab (SMT112), a bispecific PD-1/VEGF antibody for oncology in Phase III trials for non-small cell lung cancer and other solid tumors, with over 1,600 patients treated.

Who are Discuva's competitors?

Discuva's competitors and similar companies include Proof Diagnostics, IncellDx, Adrenomed, Abac Therapeutics, and DDL.

Where is Discuva headquartered?

Discuva is headquartered in United Kingdom.

How many employees does Discuva have?

Discuva has 1,000 employees 🔒.

When was Discuva founded?

Discuva was founded in 2010 🔒.

What sector and industry vertical is Discuva in?

Discuva is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Discuva

Who are the top strategic acquirers in Discuva's sector and industry

Top strategic M&A buyers and acquirers in Discuva's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Discuva?

Top strategic M&A buyers groups and sectors for Discuva include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Discuva's sector and industry vertical

Which are the top PE firms investing in Discuva's sector and industry vertical?

Top PE firms investing in Discuva's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Discuva's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Discuva's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Discuva's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Discuva include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Discuva's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Discuva?

The key public trading comparables and valuation benchmarks for Discuva include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Discuva for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Discuva with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Discuva's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Discuva with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Discuva's' sector and industry vertical?

Access recent funding rounds and capital raises in Discuva's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Discuva